Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | ALDH5A1 | P51649 | 2/20 | 0.61 |
| ▸ | ABAT | P80404 | 2/20 | 0.61 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30203126 | 1.00 | APP (0.63) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL24445666 | 0.86 | ALDH1A1 (0.61) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL6442449 | 0.85 | ALDH1A1 (0.56) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL6445440 | 0.85 | ALDH1A1 (0.56) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL8466367 | 0.82 | ALDH1A1 (0.66) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL21095690 | 0.82 | TRPA1 (0.61) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL11971265 | 0.80 | APP (0.78) | APPKDM4E | |
| SCHEMBL11971260 | 0.80 | APP (0.78) | APPKDM4E | |
| SCHEMBL3621190 | 0.80 | ALDH1A1 (0.44) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL22555972 | 0.79 | APP (0.76) | APPALDH1A1HPGDTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114634429-B | Photosensitive diamine monomer and preparation method thereof, resin containing photosensitive diamine monomer and photosensitive resin composition | 波米科技有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-114634429-A | Photosensitive diamine monomer, preparation method thereof, resin containing photosensitive diamine monomer and photosensitive resin composition | 波米科技有限公司 | 2022-06-17 | — | — | CN | claimed |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12466795-B2 | Isoindoline compositions and methods for treating neurodegenerative disease | COGNITION THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250188044-A1 | TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION | HARBIN MEDISAN PHARMACEUTICAL CO., LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| US-20250136555-A1 | HYDANTOIN COMPOUND AND MEDICAL USE THEREOF | HARBIN MEDISAN PHARMACEUTICAL CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| WO-2024175026-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL USE THEREOF | 哈尔滨三联药业股份有限公司 | 2024-08-29 | — | — | WO | disclosed |
| CN-118546109-A | Nitrogen-containing heterocyclic compound and medical application thereof | 哈尔滨三联药业股份有限公司 | 2024-08-27 | — | — | CN | disclosed |
| EP-4402124-A1 | NOVEL HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | Prosetta Biosciences, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005037207-A2 | ARYLALKYL-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE INCLUDING VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037809-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037283-A1 | FUSED-ARYL AND HETEROARYL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037279-A1 | 1- 2’ (1, 4’-BIPERIDIN-1’-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | APP 671/4885ALDH1A1 1334/4885ALDH5A1 3137/4885 |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | APP 3167/4885ALDH1A1 445/4885ALDH5A1 236/4885 |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | APP 4227/4885ALDH1A1 3991/4885ALDH5A1 4806/4885 |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | APP 4000/4885ALDH1A1 244/4885ALDH5A1 187/4885 |
| US-20250188044-A1 | TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION | PPARD, PPARA, PPARG | APP 892/4885ALDH1A1 879/4885ALDH5A1 360/4885 |
| US-12466795-B2 | Isoindoline compositions and methods for treating neurodegenerative disease | TMEM97, SLC18A2, PSD | APP 37/4885ALDH1A1 4160/4885ALDH5A1 3758/4885 |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | FAAH, HTR3A, MAOA | APP 1903/4885ALDH1A1 439/4885ALDH5A1 255/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | APP 3444/4885ALDH1A1 559/4885ALDH5A1 117/4885 |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | APP 2808/4885ALDH1A1 4359/4885ALDH5A1 4404/4885 |
| US-20250136555-A1 | HYDANTOIN COMPOUND AND MEDICAL USE THEREOF | PPARD, PPARA, PPARG | APP 1480/4885ALDH1A1 807/4885ALDH5A1 690/4885 |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | COMT, MAOA, HTR3A | APP 4317/4885ALDH1A1 434/4885ALDH5A1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.